Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2701 • 2019 ACR/ARP Annual Meeting
Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER
Sezgin Sahin ¹, Ceyhun Acari ², Hafize Emine Sonmez ³, Fatma Zehra Kilic ⁴, Erdal Sag ⁵, Hatice Adiguzel Dundar ⁶, Amra Adrovic ⁷, Selcan Demir ³, Kenan Barut ⁸, Yelda Bilginer ⁹, Betul Sozeri ¹⁰, Erbil Unsal ⁶, Seza Ozen ¹¹ and Ozgur Kasapcopur¹², ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ²Dokuz Eylul University, School of Medicine, Izmir, Turkey, ³Hacettepe University, School of Medicine, Ankara, Turkey, ⁴Umraniye Training and Research Hospital, Istanbul, ⁵Hacettepe University, Ankara, Turkey, ⁶Dokuz Eylul University, School of Medicie, Izmir, Turkey, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ⁸Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ⁹Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹⁰University of Health Sciences , Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ¹¹Hacettepe University Hospital, Ankara, Turkey, ¹²Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic childhood arthritis with onset before age of 16 and has a significant degree of morbidity that negatively…
Abstract Number: 916 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
Francesca Minoia¹, Francesca Bovis ², Sergio Davì ³, AnnaCarin Horne ⁴, Michel Fischbach ⁵, Michael Frosch ⁶, Adam Huber ⁷, Marija Jelusic ⁸, Sujata Sawhney ⁹, Deborah McCurdy ¹⁰, Clovis Artur Silva ¹¹, Donato Rigante ¹², Erbil Unsal ¹³, Nicolino Ruperto ¹⁴, Alberto Martini ¹⁵, Randy Cron ¹⁶ and Angelo Ravelli ¹⁵, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy, ²Università degli Studi di Genova, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Hopital Universitaire Hautepierre, Strasbourg, France, ⁶School of Medicine Witten/Herdecke University, Datteln, Germany, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸University of Zagreb, Zagreb, Croatia, ⁹Sir Ganga Ram Hospital, New Delhi, India, ¹⁰University of California, MDCC 12-430, 10833 Le Conte Ave, Los Angeles, 90095, CA, USA, Los Angeles, ¹¹Childrens’ Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ¹²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Dokuz Eylul University, School of Medicie, Izmir, Turkey, ¹⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD). Because…
Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Alessandra Alongi¹, Serana Calandra ¹, Susan Thornhill ², Jennifer Stinson ³, Jen Horonjeff ⁴, Daniel Horton ⁵, Alessandro Consolaro ⁶ and Esi Morgan ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ²Thornhill Associates, Hermosa Beach, USA, Hermosa Beach, ³The Hospital for Sick Children, and University of Toronto, Toronto, Canada, Toronto, ⁴Columbia University Medical Center, New York, USA, New York, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…
Abstract Number: 1125 • 2019 ACR/ARP Annual Meeting
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Joe Zhuo¹, Ying Bao ², Qian Xia ², Aarti Rao ³, Niyati Sharma ³, Xue Han ⁴ and Robert Wong ⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Lawrenceville, NJ, ³Mu Sigma, Bangalore, India, ⁴Bristol-Myers Squibb Company, Princeton, NJ, ⁵Bristol-Myers Squibb, Princeton
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a common, chronic rheumatic disease of childhood that carries substantial economic impact on patients (pts) and families1. The objective…
Abstract Number: 2704 • 2019 ACR/ARP Annual Meeting
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Kathleen Collins¹, Anava Wren ² and Tzielan Lee ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Injectable medications are frequently used to treat Juvenile Idiopathic Arthritis (JIA). Fear of pain and needle fear have been identified as barriers to injectable…
Abstract Number: 170 • 2019 ACR/ARP Annual Meeting
Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Jimin Lee¹, Dennis Newhook ², Kaylee Eady ² and Roman Jurencak ¹, ¹Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ²CHEO Research Institute, Ottawa, ON, Canada
Background/Purpose: While juvenile idiopathic arthritis (JIA) is a common pediatric rheumatic disease, there is a lack of available child-friendly patient education materials. An illustrated storybook…
Abstract Number: 1174 • 2019 ACR/ARP Annual Meeting
Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI
Teresa Giani¹, Marco Di Maurizio ², Paolo Lionetti ², Azzurra Bernardini ², Giovanna Ferrara ¹, Viola Filistrucchi ² and Rolando Cimaz ³, ¹Anna Meyer Children University Hospital, Florence, Italy, ²A. Meyer Children University Hospital, Florence, Italy, ³Meyer Children's Hospital in Florence, Florence, Italy
Background/Purpose: Sacroiliitis is one of the extraintestinal manifestations associated with inflammatory bowel disease (IBD), and may be underdiagnosed especially in the pediatric age. MR-enterography (Entero-MRI)…
Abstract Number: 2705 • 2019 ACR/ARP Annual Meeting
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis
Anne McHugh¹, Avis Chan ², Carolyn Herrera ², Margo Thienemann ² and Jennifer Frankovich ², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto
Background/Purpose: Mental health disorders are thought to be common in patients with rheumatic disease, but studies examining behavioral issues in patients with juvenile idiopathic arthritis…
Abstract Number: 187 • 2019 ACR/ARP Annual Meeting
Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort
Theresa Hennard ¹, Najima Mwase ², Amy Cassedy ³, Joseph McDonald ⁴, Virginia Utz ⁵ and Sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Division of Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati
Background/Purpose: JIA-associated uveitis (JIA-U) is the most prevalent extra-articular manifestation of JIA and the most common type of uveitis in children. To date, environmental factors…
Abstract Number: 1201 • 2019 ACR/ARP Annual Meeting
Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
Claire Barber¹, Natalie Shiff ², Cheryl Barnabe ³, Susanne Benseler ³, Ricky Chin ³, Nicole Johnson ³, Nadia Luca ³, Paivi Miettunen ⁴, Marinka Twilt ³, Dwaraka Veeramreddy ³ and Heinrike Schmeling ⁵, ¹University of Calgary, Calgary, Canada, ²University of Florida, Gainesville, FL, ³University of Calgary, Calgary, AB, Canada, ⁴Alberta Children's Hospital, Calgary, ON, Canada, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Wait time to pediatric rheumatology care for patients with Juvenile Idiopathic Arthritis (JIA) is a nationally endorsed quality measure in Canada. Target wait times…
Abstract Number: 2706 • 2019 ACR/ARP Annual Meeting
Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry
Agna Neto¹, Ana Filipa Mourão ², Filipa Oliveira-Ramos ³, Raquel Marques ³, Paula Estanqueiro ⁴, Manuel Salgado ⁴, Margarida Guedes ⁵, Daniela Piotto ⁶, Clovis Artur Silva ⁷, José Melo Gomes ⁸, Marta Cabral ⁹, Marta Conde ¹⁰, Ricardo Figueira ¹¹, Maria José Santos ¹², João Eurico Fonseca ¹³, Maria Teresa Terreri ⁶ and Helena Canhão ¹⁴, ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon; Hospital Central do Funchal, Madeira., Lisbon, Portugal, ²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ³Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Lisbon, Portugal, ⁴Pediatrics, Hospital Pediátrico Carmona da Mota, Coimbra, Coimbra, Portugal, ⁵Unidade de Imunologia Clínica, Centro Hospitalar Universitário do Porto, Porto, Portugal, ⁶Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Universidade de São Paulo, São Paulo, Brazil, ⁸Instituto Português de Reumatologia; Clínica Dr. Melo Gomes, Lisbon., Lisbon, Portugal, ⁹Pediatrics, Hospital Prof. Doutor Fernando Fonseca, Lisbon, Lisbon, Portugal, ¹⁰Pediatric Rheumatology Unit, Hospital Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Lisbon, Portugal, ¹¹Rheumatology Department, Hospital Central do Funchal, Funchal, Madeira, Portugal, ¹²Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ¹⁴CEDOC, EpiDoC Unit, NOVA Medical School, Lisbon, Lisbon, Portugal
Background/Purpose: In adults with Rheumatoid Arthritis, obesity has been associated with higher disease activity. However, in Juvenile Idiopathic Arthritis (JIA), the influence of body mass…
Abstract Number: 188 • 2019 ACR/ARP Annual Meeting
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Kristin Wipfler¹, Sofia Pedro ¹, Yomei Shaw ¹, Rebecca Schumacher ¹, Teresa Simon ², Alyssa Dominique ³, Adam Reinhardt ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Children’s Hospital & Medical Center & University of Nebraska Medical Center, Omaha, NE, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Upon transitioning from pediatric to adult care, many patients with JIA are labeled as having RA, despite the two diagnoses being distinct in care…
Abstract Number: 1814 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Gabriella Giancane¹, Valentina Muratore ², Valentina Marzetti ³, Neus Quilis ³, Belen Serrano Benavente ³, Francesca Bagnasco ³, Alessandra Alongi ⁴, Adele Civino ⁵, Alessandro Consolaro ⁶ and Angelo Ravelli ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ²IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy, ³IRCCS Gaslini, Genoa, ⁴Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ⁵Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: After nearly two decades from the start of the Biologic era, systematic analyses of patients with juvenile idiopathic arthritis (JIA) have shown a high…
Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Fabrizio De Benedetti¹, Inmaculada Calvo Penadés ², Nadina Rubio-Pérez ³, Alexey Maschan ⁴, Pierre Quartier ⁵, Zbigniew Żuber ⁶, Marina Stanislav ⁷, Raul Barria ⁸, Daniel Clemente ⁹, Gabriel Vega-Cornejo ¹⁰, Nancy Liu ¹¹, Christine Xu ¹¹, Angeliki Giannelou ¹², Bolanle Akinlade ¹² and Lydie Baret-Cormel ¹³, ¹Bambino Gesù Children’s Hospital, Rome, Italy, ²Hospital Univ. La Fe, Valencia, Spain, ³University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ⁴Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, ⁵Necker Hospital, Paris, France, ⁶Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸Bioreuma, Concepción, Chile, ⁹Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ¹⁰CREA de Guadalajara, Jalisco, Mexico, ¹¹Sanofi, Bridgewater, NJ, ¹²Regeneron, New York, NY, ¹³Sanofi, Chilly-Mazarin, France
Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].